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Background: Few large-scale studies have examined inhaled corticosteroid treatment in
preschool children with recurrent wheeze. We assessed the effects of ciclesonide in preschool
children with recurrent wheeze.
Methods: We included children 2e6 yrs with recurrent wheeze and a positive asthma predic-
tive index or aeroallergen sensitization to, excluding patients with episodic viral wheezing.
After a 2e4-week baseline period, patients with ongoing symptoms or rescue medication
use were randomised to once-daily ciclesonide 40, 80, 160 mg or placebo for 24 weeks.
Results: The number of wheeze exacerbations requiring systemic corticosteroids was unex-
pectedly low in all groups: 25 (10.2%) in placebo group, as compared to 11 (4.4%), 18 (7.3%),
and 17 (6.7%) in ciclesonide 40, 80, and 160 mg, respectively. The difference in time to first
exacerbation was not significantly different between groups (p Z 0.786), but the difference
in exacerbation rates between placebo and the pooled ciclesonide groups was (p Z 0.03).
Large and significant (p < 0.0001) improvements in symptom scores and rescue medication
use occurred in all groups, including placebo. Improvements in FEV1 and FEF25e75 (measured
in 284 4e6 yr olds) were larger in the ciclesonide than in the placebo group. No differences
in safety parameters (adverse events, height growth, serum and urinary cortisol levels)
between ciclesonide and placebo were observed.
Conclusions: In preschool children with recurrent wheeze and a positive asthma predictive
index, ciclesonide modestly reduces wheeze exacerbation rates and improves lung function.ww.clinicaltrials.gov) under no. NCT00163449.
84244165; fax: þ31 384247660.
nl (P.L.P. Brand).
1 Elsevier Ltd. All rights reserved.
Ciclesonide in preschool children 1589A large placebo response and unexpected selection of patients with mild disease may have
affected outcomes, highlighting the heterogeneity of preschool wheezing disorders.
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Although recurrent wheeze is very common in preschool
children,1,2 the evidenceon its treatment is limited.3 Inhaled
corticosteroids (ICS) appear to be effective,4 but their
effects are smaller than in older children and adolescents.3
The scant available evidence suggests that ICS effects in
preschool children may depend on wheezing phenotype,
severity, and atopic sensitization.3,5 Wheeze both during
viral colds and in response to other stimuli (multiple trigger
wheeze) improves during ICS maintenance therapy.3,5,6
Although no studies have shown ICS efficacy in patients
with episodic viral wheeze, interpretation of these data is
limited by the small number of subjects studied.3,5,7 A recent
large study showed that ICS are effective in reducing wheeze
in preschool children with a positive asthma predictive
index,8 which indicates a high risk of symptoms persisting
beyond the 6th birthday.9 In this study, children were more
likely to respond to ICS if they were male, had more severe
symptoms andwere atopic,10 confirming results from smaller
studies.6,11,12 Although the evidence on ICS effects in
preschool children and the factors associated with a favour-
able ICS response in this age group is accumulating, there is
an ongoing need of large-scale clinical trials of maintenance
treatment for preschool wheezing disorders,3 in particular
studies assessing more objective parameters of treatment
effect, such as lung function.
Ciclesonide is a once-daily ICS pro-drug that is converted
to its active form, desisobutyryl-ciclesonide, by esterases
in the airways, and is delivered from a metered dose
inhaler in a hydrofluoroalkane-based solution containing
a high proportion of fine particles.13 Studies in children
aged 6 yrs showed that ciclesonide had comparable effi-
cacy and a similar to superior safety profile when compared
to fluticasone or budesonide.14,15 Long-term safety studies
of ciclesonide in school-aged children showed no adverse
effects on adrenal function or height growth.16,17
The aim of this study was to assess the effects of three
doses of ciclesonide, versus placebo, for 24 weeks, on
wheeze exacerbations, symptom scores, and lung function
in preschool children with recurrent wheeze.
Patients and methods
This randomised, double-blind, placebo-controlled, parallel-
group study was conducted in 77 centres (Brazil, Germany,
Hungary, India, the Netherlands, Poland, South Africa, Spain
and Switzerland). The study was registered with http://
clinicaltrials.govunder number NCT00163449.
Patients
Children aged 2e6 yrs were eligible for inclusion if they had
a documented clinical history of asthma (defined as 3 ormore episodes of wheezing, or troublesome recurrent
symptoms and/or episodes wheezing, as reported by
parents) for  6 months, plus a positive stringent asthma
predicitive index9 or a positive screening test for atopy
(Phadiatop18).
Exclusion criteria included a parental report or docu-
mentation in the medical chart of one or more of the
following: previous use of systemic steroids; a respiratory
tract infection in the month before the study; a history of
exclusive episodic viral wheezing; concomitant severe
diseases; diseases impairing lung function or precluding ICS
use; >2 hospitalisations for wheezing in the past year;
history of life-threatening wheeze or mechanical ventila-
tion; premature birth; and abnormal height.
Methods: study design
Baseline period
Current ICS and non-steroidal controller (e.g., montelukast)
therapy was withdrawn before study entry, and during the
2e4 wk baseline period patients only used inhaled salbu-
tamol (100 mg/puff, inhaled by valved holding chamber,
Aerochamber Plus) on demand. All children had to
demonstrate the use of inhaler and spacer to the study staff
until these were satisfied that drug administration and
inhalation technique were correct; children aged 2e3 yrs
were equipped with a facemask (medium size Comfort
Seal facemask fitted to the Aerochamber Plus by the
manufacturer) if unable to use the inhaler with a spacer
and mouthpiece. Throughout the study, parents kept
a daily symptom diary of rescue medication use and both
daytime and nighttime symptoms on a scale ranging from
0 (no symptoms) to 4 (very bad symptoms: awake most
of the night, or unable to carry out daily activities as usual).
The total daily symptom score, therefore, ranged from
0 to 8.
Eligibility to enter the treatment period was assessed
during the last week of the baseline period. In the week
before randomisation, patients had to have a total daily
symptom score of 1 on 4 days, or used rescue medica-
tion on 4 days, indicating ongoing symptoms during
baseline.
Treatment period
When patients fulfilled the eligibility criteria at the end of
the baseline period, they were randomised to 24-wk study
treatment with placebo or ciclesonide 40 mg, 80 mg or
160 mg using a computer-generated randomisation list
following age-stratified block randomisation (2e3 yrs and
4e6 yrs). Allocation of treatment was performed by an
independent telephone centre, and was blinded to study
investigators enrolling the patients.
Study medication was dispensed via a hydrofluoroalkane-
metered-dose inhaler, one puff daily in the evening,
administered with a spacer (AeroChamber Plus). Placebo
1590 P.L.P. Brand et al.and ciclesonide inhalers were identical in appearance. Sal-
butamol 100 mg/puff could be used as reliever therapy
throughout the study. If a patient experienced insufficient
control of symptoms, montelukast was allowed as additional
medication until study end, in a once daily dose of 4 mg
chewing tablet for 2e5 year olds, and 5mg chewing tablet fro
6 year olds. During the first 12 weeks of treatment, such
insufficient control was determined by the physician of each
patient; in the final 12 weeks, montelukast treatment was
added if,within the lastweek, the cumulative daily symptom
score was 8 or rescue medication had been used 8 times.
Study endpoints and assessments
The primary efficacy endpoint was (time to) severe wheeze
exacerbation, defined as a worsening of asthma/wheeze
symptoms requiring treatment with systemic steroids as
judged by the treating physician. Patients experiencing
severe wheeze exacerbation were withdrawn from the
study.
Secondary efficacy endpoints were: percentage of
wheeze-controlled days (days without wheeze and without
use of rescue medication); daily symptom scores and use of
rescuemedication. In addition, lung functionwas assessed in
children aged 4e6 yrs able to provide reliable and repro-
ducible spirometry measurements following published
recommendations for this age group.19 Individual spirograms
were checked for acceptability and reproducibility by study
investigators, and were filed for verification purposes.
Forced expiratory volume in 1 s (FEV1), peak expiratory flow
(PEF) and forced expiratory flowduring themiddle half of the
forced vital capacity (FEF25e75) were recorded fromFigure 1 Patient disposition. ): one patient was assigned to plac
for discontinuation may have been provided for a single patient.reproducible expiratory flow-volume loops. Rescue medica-
tion was withheld for 4 h before spirometry.12
Adverse events were recorded at each study visit. If
oropharyngeal fungal infection was suspected, a throat
swab was cultured at a central laboratory. Patient height
was measured by stadiometry at the start of treatment
period, after 12 weeks’ treatment, and at study end. To
assess potential suppression of the hypothalamic-pituitary-
adrenal axis, serum and urinary cortisol levels were
measured at baseline, after 12 weeks’ treatment (urine
levels only) and study end.
Ethical and quality considerations
The study was approved by the ethical review boards of all
participating centres and was conducted according to Good
Clinical Practice guidelines and the Declaration of Helsinki.
Caregivers provided written informed consent. Study
centres, documents and the clinical study report were
audited by the Quality Assurance Department of the study
sponsor (then ALTANA Pharma, now Nycomed).
Statistical analysis
In order to be able to detect the difference in estimated
severe wheeze exacerbation rate between 25% (placebo)
and 14% (ciclesonide) with 90% power (log-rank test), and
assuming a withdrawal rate of 10% for reasons other than
severe wheeze exacerbation, 250 patients were needed in
each group. The following efficacy analyses were planned
a priori to be conducted in the intent-to-treat population.
First, the Tarone trend test examined the probability ofebo but received ciclesonide 80 mg instead; y: multiple reasons
Table 1 Demographic and clinical baseline characteristics.
Placebo
(n Z 246)
Ciclesonide 40 mg
(n Z 248)
Ciclesonide 80 mg
(n Z 245)
Ciclesonide 160 mg
(n Z 253)
Median age yrs (range) 4.0 (2.0e6.0) 4.0 (2.0e6.0) 4.0 (2.0e6.0) 4.0 (2.0e6.0)
Mean height cm (SD) 103.8 (9.8) 103.7 (10.4) 103.9 (10.4) 104.6 (10.4)
Sex n (%)
Female 86 (35.0) 84 (33.9) 85 (34.7) 116 (45.8)
Race n (%)
White 159 (64.6) 159 (64.1) 148 (60.4) 149 (58.9)
Black 8 (3.3) 7 (2.8) 11 (4.5) 14 (5.5)
Asian 43 (17.5) 44 (17.7) 44 (18.0) 45 (17.8)
Other 36 (14.6) 38 (15.3) 42 (17.1) 45 (17.8)
Median disease duration
months (range)
21.3 (4.2e70.2) 21.6 (3.8e81.1) 22.5 (5.9e79.8) 23.5 (5.9e77.1)
ICS pretreatment n (%)
Yes 140 (56.9) 143 (57.7) 138 (56.3) 135 (53.4)
Mean baseline ICS daily
dose mg (SD)a
332.0 (136.9) 353.0 (141.6) 339.7 (143.0) 335.8 (142.2)
Mean baseline FEV1 L (SD) 0.94 (0.27) 0.97 (0.30) 1.05 (0.23) 1.01 (0.28)
FEV1: forced expiratory volume in 1 s; ICS: inhaled corticosteroids; SD: standard deviation.
a Beclomethasone dipropionate equivalent.
Figure 2 Proportion of patients not experiencing a severe
wheeze exacerbation throughout the study period. CIC Z
ciclesonide; PLACZ placebo.
Ciclesonide in preschool children 1591a patient experiencing severe wheeze exacerbation before
study end in patients using ciclesonide 160 mg versus
placebo, and in the other ciclesonide groups vs placebo.
Subsequently, the proportion of patients experiencing
severe wheeze exacerbation were compared between the
pooled ciclesonide groups and the placebo group using
Fisher’s exact test. Diary data were analysed using non-
parametric methods, and lung function and stadiometry
data with analysis of covariance. A two-sided p value of
<0.05 was considered statiscally significant (referred to as
“significant” in results and discussion).
Results
Of the 1164 patients enrolled, 994 patients were rando-
mised to study treatment (Fig. 1). Two patients (one
placebo, one ciclesonide 80 mg) did not receive study
medication and were excluded from the analysis (Fig. 1).
Demographics and baseline clinical characteristics were
comparable between groups (Table 1). Mean (standard
deviation) duration of exposure to study medication was
comparable in patients receiving placebo (153.2  41.3
days), ciclesonide 40 mg (159.1  32.9), ciclesonide 80 mg
(155.3  39.2), and ciclesonide 160 mg (159.5  31.5).
Efficacy
Exacerbations
The proportion of patients experiencing severe wheeze
exacerbation in the four study groups is presented in Fig. 2.
In all groups, the occurrence of severe wheeze exacerba-
tion was considerably lower than estimated before the
study: 25 (10.2%) in placebo group, as compared to 11
(4.4%), 18 (7.3%), and 17 (6.7%) in ciclesonide 40, 80, and
160 mg, respectively. The Tarone trend test showed no
significant difference in the probability of experiencingsevere wheeze exacerbation between ciclesonide 160 mg
and placebo (p Z 0.786), nor between the other cicleso-
nide groups and placebo (p > 0.4). The difference in
exacerbation rates between the placebo (10.2%) and the
pooled ciclesonide groups (6.2%, relative risk 1.65, 95% CI
1.04e2.63), however, was significant (p Z 0.030).
Symptom scores
Highly significant increases in the percentage of wheeze-
controlled days, symptom scores and rescue medication use
were observed in all groups, including placebo (p < 0.0001),
with no significant differences between groups (Table 2).
Table 2 Changes in secondary efficacy endpoints during the study.
Placebo Ciclesonide 40 mg Ciclesonide 80 mg Ciclesonide 160 mg
Percentage of wheeze-controlled days
Within-group changes
(median)
Baseline median (IQR) 23.1 (0.0e50.0) 25.0 (0.0e50.0) 23.1 (0.0e50.0) 23.1 (0.0e50.0)
Study end median (IQR) 69.2 (3.6e100.0) 67.9 (3.7e100) 71.4 (15.4e100) 64.3 (10.7e100)
p < 0.001 p < 0.001 p < 0.001 p < 0.001
Median (95% CI) difference e 0.0 (6.4, 7.1) 3.1 (3.6, 10.4) 0.0 (7.1, 7.1)
(versus placebo), p p Z 0.827 p Z 0.363 p Z 0.986
Symptom scores
Within-group changes
(median)
Baseline median (IQR) 1.57 (0.71e2.86) 1.29 (0.71e2.57) 1.50 (0.71e3.00) 1.43 (0.71e2.86)
Study end median (IQR) 0.71 (0.00e2.57) 0.57 (0.00e2.29) 0.57 (0.00e2.43) 0.71 (0.00e2.29)
p p < 0.001 p < 0.001 p < 0.001 p < 0.001
Median (95% CI) difference e 0.00 (0.29, 0.14) 0.10 (e0.29,0.14) 0.01 (e0.29,0.14)
(versus placebo), p p Z 0.893 p Z 0.373 p Z 0.544
Rescue medication use
(puffs per day)
Within-group changes
(median)
Baseline median (IQR) 1.00 (0.29e2.57) 1.00 (0.14e2.43) 1.14 (0.14e2.86) 1.00 (0.14e2.71)
Study end median (IQR) 0.29 (0.00e2.00) 0.14 (0.00e2.00) 0.14 (0.00e2.71) 0.29 (0.00e2.14)
p-value p < 0.0001 p < 0.0001 p < 0.0001 p < 0.0001
Median (95% CI)
difference
e 0.00 (0.14, 0.29) 0.14 (e0.29,0.14) 0.00 (0.29, 0.14)
(versus placebo), p p Z 0.889 p Z 0.394 p Z 0.923
IQR: interquartile range.
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Reliable lung function measurements were obtained in 284/
544 (52.2%) of the 4e6-yr-olds. There was a clear trend
showing better lung function in ciclesonide-treated patients
than in those receivingplacebo, and this reached significance
in a number of comparisons (Fig. 3).
Subgroup analysis: Asian and non-Asian patients
In an attempt to identify factors potentially explaining the
unexpectedly low exacerbation rates and the pronounced
placebo response, post hoc analyses were carried out,
showing marked differences in baseline clinical character-
istics between Asian and non-Asian patients (Table 3).
Fewer Asian patients were pretreated with ICS, and the
proportion of patients with personal or family history of
asthma or atopy was lowe among Asians than among non-
Asians (Table 3). In addition, severe morbidity was less
common in Asians (89/170, 52.3%) than in non-Asians (502/
814, 61.7%).
Safety
Adverse event profiles with all ciclesonide doses were
comparable with placebo. Culture-proven oral candidiasis
was found in 9 patients (3 in placebo, and 3, 2, and 1 in
ciclesonide 40, 80, and 160 mg, respectively), dysphonia in 4
(2, 1, 0, 1). Mean growth rates were higher with ciclesonide
than placebo, but differences were not significant. Noclinically relevant changes in cortisol levels were detected,
and differences between groups were not significant.
Discussion
In this large trial, ciclesonide modestly reduced wheeze
exacerbation rates, and improved lung function in
preschool children with recurrent wheeze and a positive
API or atopy. The risk of severe wheeze exacerbation was
lower in children using ciclesonide (10.4%) than in those
on placebo (16.2%, p Z 0.017, number needed to treat
16). No effects of ciclesonide on symtom scores and
rescue medication use were found. Although we
purposefully recruited a patient population with a high
risk of wheeze persistence, and patients were suffering
from ongoing symptoms when randomized to study treat-
ment, the wheeze exacerbation rate in this study was
considerably lower than estimated based on previous
clinical trials in this age group,4,8 and an unexpectedly
large placebo response was observed which may have
obscured beneficial effects of ciclesonide therapy on
symptom scores.
Previous studies have demonstrated the effectiveness of
ciclesonide in older children (4e15 yrs) and adults with
asthma, regardless of disease severity.14-16,20 It seems
unlikely, therefore, that the limited influence of cicleso-
nide on symptoms in this study was due to lack of an anti-
inflammatory effect of the drug. Although a recent meta-
Figure 3 Change in lung function at study end compared with baseline. FEF25e75: forced expiratory flow during the middle half of
the forced vital capacity; FEV1: forced expiratory volume in 1 s; PEF: peak expiratory flow; SEM: standard error of the mean;
): p < 0.05 versus placebo.
Ciclesonide in preschool children 1593analysis of preschool wheezing studies showed superiority
of ICS over placebo, there was a high degree of clinical and
statistical heterogeneity between studies,4 illustrating that
the interpretation and pooling of results from such studies
are hampered by several methodological problems.3 In
addition, the role of inflammation as a pathophysiological
mechanism in preschool children with recurrent wheeze is
poorly understood. Recent studies showed that acute viral-
induced wheezing in preschool children did not respond to
oral prednisolone,21 and that preschool children with
transient wheeze had higher exhaled nitric oxide levels
than children with persistent wheeze.22 Therefore, it
remains unclear in what way and in which subgroups of
preschool children with recurrent wheeze ICS may be
beneficial.
To date, the lack of a uniformly accepted classification
system for preschool wheeze has hampered comparison ofTable 3 Baseline risk factors for asthma in Asian and non-Asian
n (%) of
patients with
Placebo
(n Z 246)
Ciclesonide 40 m
(n Z 248)
History of allergies
Asian 17 (39.5)* 16 (36.4)
Non-Asian 118 (58.1) 106 (52.0)
History of eczema
Asian 3 (7.0)** 5 (11.4)**
Non-Asian 101 (49.8) 104 (51.0)
Nasal symptoms outside colds
Asian 22 (51.2) 18 (40.9)*
Non-Asian 106 (52.2) 120 (58.8)
Family history of asthma
Asian 39 (90.7)** 40 (90.9)*
Non-Asian 145 (71.4) 154 (75.5)
ICS pretreatment
Asian 20 (46.5) 14 (31.8)**
Non-Asian 120 (59.1) 129 (63.2)
Numbers of Asian and non-Asian patients in each group were: placebo
and 210; ciclesonide 160 mg, 45 and 208.
*p < 0.05, **p < 0.01 when comparing Asians to non-Asians.study results in this age group. The ERS task force guide-
lines recommendation to distinguish multiple trigger
wheeze from episodic viral wheeze was largely based on
a systematic review which concluded that ICS therapy
improved symptoms in preschool children with multiple-
trigger wheeze, but not in children with episodic viral
wheeze.5 However, it was noted that this conclusion was
based on a small number of studies with small sample
sizes.3 Recently, it has been shown that patterns of wheeze
may change over time in preschool children,23 reducing the
value of the distinction between episodic viral and multiple
trigger wheeze. In addition, this distinction does not take
severity or frequency of exacerbations into account.24,25
This study was designed to include preschool children
with recurrent wheeze with a high risk of wheeze persisting
beyond the 6th birthday,9 and with relatively severe
disease, expressed as ongoing symptoms during baseline.patients.
g Ciclesonide 80 mg
(n Z 245)
Ciclesonide 160 mg
(n Z 253)
21 (47.7) 21 (46.7)
107 (53.2) 122 (58.7)
2 (4.5)** 5 (11.1)**
87 (43.3) 74 (35.6)
14 (31.8)* 13 (28.9)**
113 (56.2) 113 (54.3)
36 (81.8) 38 (84.4)
148 (73.6) 156 (75.0)
22 (50.0) 15 (33.3)**
116 (55.2) 120 (57.7)
, 43 and 203, ciclesonide 40 mg, 44 and 204; ciclesonide 80 mg, 44
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medication use seen in children treated with placebo, and
the much lower rates of wheezing exacerbations than those
found in earlier studies suggest however that the patients
recruited had milder disease than expected. It is likely that
caregivers are reluctant to allow young children to partic-
ipate in placebo-controlled trials, especially when their
child has severe disease, and that this caused the recruit-
ment of patients with milder disease in our study.26 This
was particularly apparent in Asian patients, who differed
from non-Asian patients in risk factors and disease severity
(Table 3). This suggests that there are international varia-
tions in diagnosis and classification of preschool wheezing
disorders. Taken together, these issues indicate that the
current classification system for preschool wheezing
requires improvement, preferably including objective
criteria such as lung function or markers of atopy or
inflammation.26
Placebo responses like the one we found (Table 2) may
occur both in objective and subjective measures of disease
activity,27 and tend to increase with a later date of study
publication.28 The latter effect is thought to be caused by
increasing participation in clinical trials of individuals with
milder disease.28 This may also apply to ICS in preschool
children because these drugs are increasingly prescribed to
preschool children with non-specific recurrent respiratory
symptoms.3,29,30 Because it is not always easy to distinguish
wheeze associated with lower airway obstruction in young
children from upper airway noises and other non-specific
respiratory symptoms like cough and breathlessness,3 chil-
dren with such non-specific symptoms may have been
recruited into this study, and that spontaneous improve-
ment of these symptoms over time (regression to the mean)
may help to explain the limited effect of ciclesonide on
symptoms in this study.
Ongoing concerns exist regard systemic side effects of
ICS, particularly in young children.31,32 In this large and
long-term study, we found no effects of any ciclesonide
dose on height growth or adrenal function, confirming
previous studies of ciclesonide in older children.17,33
Few studies to data have used lung function as an
outcome measure in preschool children. In agreement with
previous smaller sample studies, more than half of the 4e6-
yr-olds in this study were able to provide reproducible lung
function measurements.34,35 Routine incorporation of
spirometry measurements into future trials involving chil-
dren 4 yrs old should be considered.
In conclusion, this large, randomised, placebo-controlled
study showed modest effects of ciclesonide on exacerbation
rates and lung function in preschool children with recurrent
wheeze and a positive asthma predictive index or atopy. An
unexpectedly large placebo response and unintended
recruitment of patients with mild diseasemay have affected
outcomes. This illustrates that preschool wheezing disorders
are highly heterogeneous, and that their classification
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